Physicochemical Properties
Molecular Formula | C76H123N21O20S |
Molecular Weight | 1682.98 |
CAS # | 1228447-26-4 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
ln Vitro | ATWLPPRAANLLMAAS (V3) (25-200 μM; 12-24 h) inhibits the proliferation, viability, migration and invasion of human HCC (SMMC-7721, Huh-7) cells by inhibiting the Ras/Raf/MEK/ERK signaling pathway, however, no significant effect was observed in HL-7702 cells[2]. ATWLPPRAANLLMAAS (200 μM; 24 h) increased apoptosis and decreased the protein levels of H-RAS, phosphorylated (p)-RAF, p-MEK and p-extracellular signal-regulated protein kinase (ERK) in human HCC (SMMC-7721, Huh-7) cells[2]. Cell Migration Assay [2] Cell Line: HL-7702, SMMC-7721, Huh-7 Concentration: 25, 50, 100, 200 µM Incubation Time: 12h, 24 h Result: Inhibited the migration of SMMC-7721 and Huh-7 cells in a dose-dependent manner, but had no effect on HL-7702 cells. |
ln Vivo | ATWLPPRAANLLMAAS (160-480 μg/kg; sc; once a day for 7 consecutive days) can significantly inhibit the growth of mouse sarcoma S180 and H22 liver cancer xenografts in a dose-dependent manner [1]. ATWLPPRAANLLMAAS (200 μg/kg; sc; once a day for 4 weeks) inhibits the growth of human HCC xenografts by downregulating angiogenesis and upregulating apoptosis [2]. |
Cell Assay |
Apoptosis Analysis[2] Cell Types: SMMC-7721, Huh-7 Tested Tested Concentrations: 200 μM Incubation Duration: 24 h Experimental Results: Remarkably increased the apoptotic index, protein expressions of cleaved caspase-3, 8, 9, cleaved PARP, as well as Bax/Bcl-2 and Bad/Bcl-xl ratios. |
References |
[1]. Anti-tumor effects of a novel chimeric peptide on S180 and H22 xenografts bearing nude miceJ. Peptides, 2010, 31(5): 850-864. [2]. Peptide V3 inhibits the growth of human hepatocellular carcinoma by inhibiting the Ras/Raf/MEK/ERK signaling pathwayJ. Journal of Cancer, 2019, 10(7): 1693. |
Solubility Data
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.5942 mL | 2.9709 mL | 5.9418 mL | |
5 mM | 0.1188 mL | 0.5942 mL | 1.1884 mL | |
10 mM | 0.0594 mL | 0.2971 mL | 0.5942 mL |